EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

What Is Wrong with the Blood Pressure Target Recommendation of KDIGO 2021 for Hypertension in Chronic Kidney Disease?

Tukaram Jamale, Manjunath Kulkarni, Vaibhav Keskar

Nephron · 2023

DOI: 10.1159/000531029 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nephron, 2023. Verfasst von Tukaram Jamale und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Seth GS Medical College and KEM Hospital, Mumbai, India. Hauptthemen laut MEDLINE: Hypertension, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context: Eighty-five percent of patients with chronic kidney disease (CKD) have hypertension, and blood pressure (BP) control is the cornerstone in the management of CKD. Although it is widely accepted that BP should be optimized, BP targets in CKD are not known. Subject of Review: Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for the management of BP in CKD (Kidney Int. 2021 Mar 1;99(3S):S1–87) recommends targeting BP to less than 120 mm Hg systolic for patients with CKD. Second Opinion: KDIGO BP target differs from all other hypertension guidelines. This is also a major change from the previous recommendation which was <140 systolic to all patients with CKD and <130 systolic for those with proteinuria. Targeting systolic BP to less than 120 mm Hg is hard to substantiate based on available data and is based primarily on subgroup analysis of a randomized control trial. Intensive BP lowering as suggested by the guidelines may lead to polypharmacy, added cost burden, and risk of serious harms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionRenal Insufficiency, ChronicHumansBlood PressureProteinuriaAntihypertensive Agents

Stichwörter der Autor:innen

Blood pressureCardiovascular riskChronic kidney diseaseHypertension

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • Department of Nephrology, Seth GS Medical College and KEM Hospital, Mumbai, India.
  • Department of Nephrology, Father Muller Medical College, Mangaluru, India.
  • Department of Nephrology, Kokilaben Dhirubhai Ambani Hospital, Navi Mumbai, India.

Zitieren

APA

Jamale, T., Kulkarni, M., & Keskar, V. (2023). What Is Wrong with the Blood Pressure Target Recommendation of KDIGO 2021 for Hypertension in Chronic Kidney Disease?. Nephron. https://doi.org/10.1159/000531029

Vancouver

Jamale T, Kulkarni M, Keskar V. What Is Wrong with the Blood Pressure Target Recommendation of KDIGO 2021 for Hypertension in Chronic Kidney Disease?. Nephron. 2023. doi:10.1159/000531029

BibTeX
@article{Jamale2023,
  author = {Jamale, Tukaram and Kulkarni, Manjunath and Keskar, Vaibhav},
  title = {What Is Wrong with the Blood Pressure Target Recommendation of KDIGO 2021 for Hypertension in Chronic Kidney Disease?},
  journal = {Nephron},
  year = {2023},
  doi = {10.1159/000531029}
}
Kostenlos starten →